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Abstract
Background: The aim of this study was to assess curative effect of hysteroscopic and laparoscopic myomectomy
for type II submucous myomas between 3 and 5 cm in diameter and explore the optimal surgical indications.
Methods: A retrospective analysis was performed of those who underwent hysteroscopic or laparoscopic myomectomy
from January 2008 to January 2013. The patients were divided into three subgroups according to the myomas diameter
(namely, 30 mm ≤myomas diameter <40 mm; 40 mm ≤myomas diameter <50 mm; and myomas diameter ≥ 50 mm).
Clinical data such as operation time, amount of bleeding, postoperative anal exsufflation time, hospital stay, and
complications were collected.
Results: There was no significant difference regarding operation time and amount of bleeding in two groups.
We found significant difference in hysteroscopic group (within-subgroup) difference regarding operation time
and amount of bleeding, whereas no significant difference in the laparoscopic group, while significant differences
between-subgroup differences regarding operation time. Complete removal of myoma was seen in all patients.
Conclusions: Both techniques are feasible for type II submucous myomas. Laparoscopic operation has higher
advantages in type II submucous myomas of greater than 4 cm in diameter whereas hysteroscopic operation has
higher advantages in type II submucous myomas of lower than 4 cm in diameter.
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Background
Uterine myomas are the most common benign tumors
of the female genital tract affecting approximately 30 %
of women by the age of 35 and 70–80 % of women
aged ≥ 50 [1, 2]. Depending on their location in the
uterus, they may be subserous, intramural, or submucous.
Submucous myomas account for 5.5 % to 10 % of all uter-
ine myomas [3]. Submucous myomas are sub-classified into
type 0, I and II depending on the degree of intramural in-
volvement. Type 0 myoma is entirely in the endometrial
cavity, type I myoma extends less than 50 % into the myo-
metrium and type II myoma extends greater than 50 % into
the myometrium [4, 5]. It may induce severe clinical
symptoms such as abnormal menstrual bleeding, infertility,
pelvic pain, and dysmenorrhea [6–8].
A variety of therapeutic options are available for submu-
cous myomas, such as myomectomy (using laparotomic,
laparoscopic or hysteroscopic access), subtotal or total
hysterectomy (by laparotomy or laparoscopy). With the
popularization of the concept of the minimal-access surgi-
cal techniques, hysteroscopic and laparoscopic operations
have predominated in recent years [9–11]. Currently, it is
possible to treat symptomatic submucosal myomas less
invasively, with good results, with hysteroscopic myomec-
tomy [5, 12–15]. However, the current literature has
revealed some limits of the hysteroscopic approach to
treating submucous myomas such as the size, location,
and position of the myoma [13, 16] and associated with
risks such as longer operation time, incomplete removal
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of myomas, and uterine perforation. Laparoscopic myo-
mectomy (LM) is considered one of the major break-
throughs because of the proven advantages with respect
to post-operative pain and the shorter hospitalization and
convalescence and for the cosmetic reasons [17]. However,
it involves the repair of myometrium and removal of
myoma from the abdomen and thus it requires more tech-
nical skill than many other laparoscopic procedures.
Hence, it is a debated surgical procedure for laparoscopic
physicians and is relatively time-consuming that may
induce greater blood loss compared to the traditional
open operations [18–20]. But with the improvement of
surgical skills, the indications of laparoscopic myomec-
tomy have broadened gradually, especially for large
submucous myoma. In this study, we assessed the clin-
ical efficacy and safety of hysteroscopic and laparo-
scopic myomectomy for submucous myomas between 3
and 5 cm in diameter. In addition, the optimal indica-
tions of these two surgical approaches for submucous
myomas were also discussed.
Methods
Patients
The study was approved by the institutional review
board of the 260th Hospital of PLA and conducted in
accordance with the Declaration of Helsinki. Written
informed consent was obtained from each patient. We
retrospectively analyzed the clinical data of patients with
type II submucous myomas between 3 and 5 cm in diam-
eter treated with hysteroscopic or laparoscopic myomec-
tomy at our hospital from January 2008 to January 2013.
Type II submucous myomas in this study was sessile with
an intramural extension of at least 50 % [21]. The diagno-
sis of type II submucous myomas in this study was deter-
mined by ultrasound and hysteroscopic examination
according to the European Society of Hysteroscopy classi-
fication [21, 22].
The inclusion criteria was as follows: (1) patients with
menorrhagia, secondary anemia, and infertility; (2) single
type II submucosal myomas s with diameter between 3
and 5 cm; (3) the free myometrial margin (FMM) had to
be at least 2 mm; (4) patients with uteri of less than
10 weeks and uterine cavity depth ≤ 12 cm; (5) preoperative
examination showing uterine fibroid without endometrial
lesions; (6) Thinprep cytology test (TCT) showing no ma-
lignant lesions of the uterine cervix.
The exclusion criteria was shown as follows: (1) patients
who are contraindicated to hysteroscopic and laparoscopic
operation; (2) patients who fail to achieve adequate cervical
dilatation due to cervical scar; (3) patients who cannot
undergo hysteroscope placement due to minimal angle
between uterine body and cervix uterus; (4) reproductive
tract infections at acute phase; (5) Type I submucous
myomas with or without sessile; (6) subserous myoma; (7)
uterine adenomyoma; and (8) a FMM of 2 mm or lower.
Operative technique
All patients underwent preoperative assessment, includ-
ing detailed medical history, pelvic examination, ultra-
sound examinations with the use of transvaginal probes
(3.5 ~ 7.0 MHz), and diagnostic hysteroscopy using a
2.9-mm 30° rod lens hysteroscope (26120 BA; Karl Storz,
Tuttlingen, Germany). All procedures were performed
by a senior endoscopic physician and a skillful assistant.
Hysteroscopic myomectomy
Under combined spinal-epidural anesthesia, the oper-
ation was performed with the patient placed in the lith-
otomy position. Under the monitoring of the location of
the myomas and uterine intramural wall, the cervix was
dilated up to a size of 12-mm with metal dilator. An
operative hysteroscope (Karl Storz, 140 Tuttlingen,
Germany) with a 12 mm external diameter was inserted.
The uterus cavity was distended by 5 % dextrose in
normal saline solution installed by automatic fluid pump
(Endomat, Karl Storz, Tuttlingen, Germany). After detect-
ing protuberance region or white region of the mucosa by
hysteroscope and ultrasound images, the protuberance
region or white region of the mucosa parallel to the uter-
ine wall was dissected and then removed with a 90-degree
loop electrode (cutting power, 80 W; electrocoagulation
power, 60 W). After exposing the myomas nucleus follow-
ing the dissection of the myomas endometrium, the appli-
cation of electric knife should be positioned on the
myomas nucleus avoiding the injury to the surrounding
muscular layer around the myomas. For type II submu-
cous myomas with myomas diameter of greater than
4 cm, oxytocin was intravenous injected with a maximal
usage of 30 units. Electric knife stimulation and the appli-
cation of oxytocin can induce uterine contraction and
extrude the myomas nucleus to uterine cavity. Under this
condition, edge cutting of the myomas nucleus that pro-
truding into the uterine cavity was performed using
electric knife. After most part of myomas nucleus was
removed, the middle long narrow part (residual part) of
the myomas nucleus was kept. Then the residual myomas
nucleus which has protruded into the uterine cavity was
clipped out using a toothed ring forceps and pulled out
from myomas pseudocapsule bluntly and finally was
resected completely. After surgery, “O” type (inert metals)
intrauterine device was placed on the uterine cavity.
Estradiol Valerate (Bayer Schering Pharma AG, Berlin,
Germany) was administered orally on a fixed postoper-
ative dosing schedule 3 mg q12h for 21 days. If there
exists breakthrough bleeding, 3 courses of sequential
therapy was administered to promote the uterine endo-
metrium growth consisting of oral medroxyprogesterone
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acetate (Zhejiang Xianju Pharmacy Ltd, Zhejiang, China)
at 6 mg once daily for 10 days. The location of the myoma
and uterus wall was monitored with B-mode ultrasound
throughout the whole course of procedure. Patients who
had large amount of bleeding underwent uterine compres-
sion with an intrauterine Bakri balloon (Cook Medical,
Bloomington, IN).
Laparoscopic myomectomy
The surgeries were performed under general anesthesia
with the patient in head down and lithotomy position.
Veress needle is inserted periumbilically to establish an
artificial pneumoperitoneum. With a pneumoperito-
neum pressure of 12–14 mm Hg, a 10-mm trocar was
placed in the upper edge of umbilicus after removal of
the Veress needle. Video-laparoscopy was introduced
after inspection of the abdominal cavity. We used three
accessory ports: the first and second ports were inserted
from the left side of the abdomen (15 mm and 5 mm),
and the third port inserted from the right side of the
abdomen (5 mm). According to preoperative ultrasonic
positioning findings, the location of the submucous
fibroid was determined at laparoscopy. 6 μ diluted hypo-
physin was injected into the intramural wall. A unipolar
electrode was used to dissect the superficial muscular
layer overlying the myoma. The incision was extended
to the surface of the tumor nucleus. The capsule overly-
ing myoma was separated bilaterally carefully. The
grasping forceps were used to enucleate the myoma by
gentle traction and countertraction until the myoma was
enucleated completely. Attention should be paid while
enucleating the myoma to prevent damage to the under-
lying endometrium. Myoma capsule protruding into the
uterine cavity was dissected bluntly. When enucleating
the myomas completely, the endometrium will protrude
into the tumor cavity. In case that the endometrium was
damaged, it was closed with 2–0 Vicryl (Johnson &
Johnson, New Brunswick, New Jersey). The superficial
myometrium is closed with an interrupted absorbable
layer of 1–0 Vicryl (Johnson & Johnson, New Brunswick,
New Jersey). Serosal layer is sutured with 3–0 continu-
ous absorbable subcuticular sutures. All procedures were
video monitored, and all resected specimens were sent
for histologic analysis.
Follow up and assessment index
The patients were followed up at 1, 3, 6 months and
thereafter every 6 months postoperatively. The follow up
contents included the conditions of menstruation, ab-
dominal pain, secondary dysmenorrhea, etc. Transva-
ginal ultrasonography examination was conducted to
inquire myometrium echo and whether there exists
myomas recurrence. For patients whose endometrium
was damaged during hysteroscopic or laparoscopic
operations, hysteroscopic examinations were used to
inquire the morphology of the uterine cavity and if
there exists scars or polypus on the primary myomas
location after operation.
In this study, the following parameters were observed
operation time, the amount of bleeding during operation,
postoperative anal exsufflation time, postoperative recur-
rence, the days of hospital stay and all potential possible
complications such as trans urethral resection of prostate
(TURP) syndrome, infection, uterine perforation, omental
emphysema, mesenteric contusion, intrauterine adhesion,
secondary dysmenorrhea, and adenomyosis.
Operating time of the hysteroscopic operation was
defined from the initial insertion of the hysteroscopy
until the operation is over. Operating time of the laparo-
scopic operation was defined from the initial incision of
the skin until the operation is over. The amount of bleed-
ing during hysteroscopic operation was estimated using
following equation: (preoperative hematocrit (HCT)-intra-
operative HCT)/(preoperative HCT ×Weight (Kg) × 7 %).
The amount of bleeding during laparoscopic operation
was measured volume of the suction fluid minus applied
flushing fluid.
Statistical analysis
All data were analyzed using SPSS16.6 statistical software
(SPSS Inc., Chicago, IL). Categorical data was expressed as
frequency or percentage and compared with χ2 test. Con-
tinuous data was expressed as the mean ± standard devi-
ation and compared using t test or analysis of variance as
appropriate. A P value of less than 0.05 was considered
statistically significant.
Results
A total of 85 patients with type II submucous myomas
between 3 and 5 cm in diameter treated with hystero-
scopic or laparoscopic myomectomy. Of the 85 patients
with type II submucous myomas, 40 cases were treated
with hysteroscopic myomectomy (hysteroscopic group)
while the remaining 45 cases were treated with laparo-
scopic myomectomy (laparoscopic group). The mean
age of patients in hysteroscopic group and laparoscopic
group was 32.62 ± 11.42 years old and 33.41 ± 10.51 years
old, respectively. The mean myoma diameter of patients
in hysteroscopic group and laparoscopic group were
4.04 ± 0.96 cm and 4.13 ± 0.87 cm, respectively. There
was no statistically significant difference regarding to the
age, BMI, parity, fibroid diameter and comorbidities
between the hysteroscopic and laparoscopic groups
(Table 1).
Perioperative data
Perioperative data in the hysteroscopic and laparoscopic
group was reported in Table 2. There was no statistically
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significant difference regarding the operation time and
amount of bleeding during operation between the two
groups. The postoperative anal exsufflation time was sig-
nificantly higher in the laparoscopic group (22.41 ± 4.25 h)
than the hysteroscopic group (11.65 ± 3.21 h, P < 0.01). The
hospital stays was significantly higher in the laparoscopic
group (5.56 ± 1.24 days) than the hysteroscopic group
(3.23 ± 1.65 days, P < 0.01). When the patients in the
hysteroscopic and laparoscopic group were further
divided into three different subgroups according to
myomas diameter (namely, Group A, 30 mm ≤myo-
mas diameter <40 mm; Group B, 40 mm ≤myomas
diameter <50 mm; and Group C, myomas diameter ≥
50 mm), we found statistically significant within-subgroup
differences regarding operation time and amount of
bleeding in the hysteroscopic group (P < 0.05) and no
statistically significant difference in above parameters
(including operation time, amount of bleeding, postop-
erative anal exsufflation time, and hospital stays) in the
laparoscopic group (all P >0.05). Regarding between-
subgroup comparisons, we observed statistically signifi-
cant differences in operation time between all three
subgroups (Group A, B, and C) and the amount of
bleeding between two subgroups (Group B, and C).
Perioperative data in the different subgroups among
hysteroscopic and laparoscopic group were shown in
Table 3.
Three patients in the hysteroscopic group required a
second surgery. Of these, two patients with a myomas
diameter of 50 mm underwent second hysteroscopic
operation 2 months after the operation. The remaining
patient with a myomas diameter of 38 mm underwent
second hysteroscopic operation 1 month after the oper-
ation. Finally the myomas were completely removed.
Complete removal of myoma was observed in all of the
patients in the laparoscopic group. Histologic examin-
ation of the resected tissue showed benign uterine myo-
mas in all patients.
Postoperative outcomes
Table 4 showed the postoperative outcomes. Postoperative
recurrent myomas were not seen in any patients of the
two groups. None of the patient occurred TURP syn-
drome and uterine perforation. Among the 45 patients in
laparoscopic group, 1 case occurred omental emphysema
and 2 cases occurred mesenteric contusion during oper-
ation and recovered to normal after operation.
One patient in laparoscopic group experienced an
accidental pregnancy 14 months after the operation. The
patient had a uterine scar less than 2 years which had
the risk of hysterorrhexis. But she insisted on the preg-
nancy and finally delivered an infant following cesarean
section at full term. In addition, there were 3 patients in
laparoscopic group and 4 patients in hysteroscopic
group had a full-term pregnancy 2 years after the oper-
ation. Five patients in hysteroscopic group occurred mild
intrauterine adhesion 1 month after the operation. Of
these, 2 cases achieved reduction of adhesions following
uterine distention while the remaining 3 cases relieved
adhesions with scissor. Two patients in laparoscopic
group occurred mild intrauterine adhesion 1 month after
the operation and achieved reduction of adhesions
following uterine distention. None of the patient in the
two groups occurred secondary dysmenorrhea, and
adenomyosis.
Discussion
Hysteroscopic myomectomy is the preferred method
when fibroids are submucosal or when most of an intra-
mural fibroid protrudes into the uterine cavity [9]. Hys-
teroscopic resection of submucous fibroids is considered
as a simple, well-tolerated and effective procedure [23].
However, the number and the size of myomas play a
crucial role in completing the hysteroscopic myomec-
tomy [14]. For type II submucous myomas, there exist
some surgical difficulties during hysteroscopic operation.
Therefore, if laparoscopic resection can be used as an
Table 1 Baseline data in two groups
Index Hysteroscopic
group (n = 40)
Laparoscopic
group (n = 45)
P values
Age(years) 32.62 ± 11.42 33.41 ± 10.51 0.74
BMI 23.66 ± 3.58 23.41 ± 3.38 0.74
Parity
Nulliparous 6 7 0.94
Parous 34 38 0.94
Myoma diameters (cm) 4.04 ± 0.96 4.13 ± 0.87 0.65
Comorbidity
Diabetes 9 (25.50 %) 12 (26.67 %) 0.66
Hypertension 8 (20.00 %) 12 (26.67 %) 0.47
BMI Body Mass Index
Table 2 Perioperative data in the hysteroscopic and laparoscopic group
Hysteroscopic group (n = 40) Laparoscopic group (n = 45) P values
Operation time (min) 56.78 ± 16.48 62.21 ± 20.12 0.18
Amount of bleeding during operation (ml) 78.25 ± 35.18 85.87 ± 20.23 0.22
Postoperative anal exsufflation time (h) 11.65 ± 3.12 22.41 ± 4.25 0.00
Hospital stays (days) 3.23 ± 1.65 5.56 ± 1.24 0.00
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alternative surgical approach to remedy the limits of
hysteroscopic is worthwhile exploring problem.
Rakesh et al. reported that laparoscopic myomectomy
for large submucous myoma is a technically feasible pro-
cedure and suggest that it is appropriate for the experi-
enced laparoscopic surgeons to look at the indications of
the laparoscopic myomectomy [24]. In this study, we
compared the clinical data of patients who underwent
the laparoscopic and hysteroscopic myomectomy for
type II submucous myomas equal or greater than 30 mm
in diameter, and found no significant difference regarding
the operation time and amount of bleeding between the
two techniques. These findings suggest that these two
techniques have achieved similar technical efficacy in
these selected patients. However, when patients were
further divided into 3 groups according to the diameter of
the myomas, we found that hysteroscopic myomectomy
have higher advantages in type II submucous myomas of
lower than 40 mm in diameter in relation to operation
time and postoperative recovery and whereas laparoscopic
myomectomy had higher advantages in type II submucous
myomas of equal or greater than 40 mm in diameter in
relation to operation time, amount of bleeding. In
addition, we found that 3 patients (myomas diameter
50 mm, 50 mm, and 38 mm, respectively) undergoing
hysteroscopic myomectomy required secondary surgery
and one-off surgical removal of myomas was obtained in
patients receiving laparoscopic myomectomy. Our find-
ings are partially consistent with the previous report
which suggests that only the diameter greater than
3 cm in type II submucous myoma is correlated to a
higher risk of a multiple procedure during the hystero-
scopic myomectomy [14].
Hysteroscopic myomectomy is considered as the first-line
conservative therapeutic option for the treatment of pro-
lapsed pedunculated submucous myomas [25]. However,
for patients who are not suitable for hysteroscopic surgery,
laparoscopic myomectomy should be considered for sur-
geons with experienced surgical skills. Previous studies
reported that for patients with type II submucous myomas
in whom the size of the myoma was equal or greater than
40 mm, the surgeon should select the optimal surgical
approach with discretion according to the patients’ condi-
tions and its own technical level [26, 27]. The aforemen-
tioned findings in this study suggest the advantage of
laparoscopic myomectomy in the type II submucous myo-
mas equal or greater than 40 mm. The evidence for sup-
porting the laparoscopic myomectomy for the treatment of
type II submucous myomas equal or greater than 40 mm
include: 1) improved accuracy of positioning of the myomas
with the development of the ultrasound techniques; 2) the
myomas can be detected and resected accurately at the best
position with the laparoscopy or robotic-assisted laparos-
copy; 3) intraoperative injection of hypophysin into the
intramural wall helps to hemostasis; 4) complete removal
of myomas with little bleeding and the intact of the uterine
mucosa and 5) tumor cavity can be sutured well under the
laparoscopy or robotic-assisted laparoscopy, with the ad-
vantages of clear view, accurate counterpoint and good
healing outcomes after surgery. However, due to the limited
sample of included patients and the retrospective design of
Table 3 Perioperative data in the different subgroups among hysteroscopic and laparoscopic group





Hysteroscopic group (n = 40)
Group A (n = 19) 45.66 ± 13.31 42.23 ± 23.21 11.21 ± 1.87 3.12 ± 1.20
Group B (n = 15) 65.67 ± 20.32 95.54 ± 33.32 10.87 ± 1.56 3.23 ± 1.11
Group C (n = 6) 76.24 ± 16.73 105.25 ± 32.87 11.22 ± 2.15 3.45 ± 1.42
P values 0.0003 0.0000 0.8449 0.8035
Laparoscopic group (n = 45)
Group A (n = 27) 59.46 ± 18.23a 64.65 ± 25.33 21.23 ± 1.65 5.10 ± 1.20
Group B (n = 12) 56.74 ± 10.23a 74.47 ± 44.78a 21.34 ± 1.76 5.43 ± 1.19
Group C (n = 6) 62.46 ± 10.65a 76.43 ± 42.54a 22.42 ± 1.34 5.33 ± 1.47
P values 0.7573 0.5940 0.2831 0.8202
a,compared to hysteroscopic group; Group A, 30 mm≤myomas diameter <40 mm; Group B, 40 mm ≤myomas diameter <50 mm; Group C, myomas diameter≥ 50 mm
Table 4 Postoperative outcome of patients treated with
hysteroscopic or laparoscopic myomectomy
Index Hysteroscopic
group (n = 40)
Laparoscopic
group (n = 45)
Residual or recurrent myomas 0 (0 %) 0 (0 %)
Complications 5 (16.1 %) 5 (11.1 %)
Omental emphysema 0 (0 %) 1 (2.2 %)
Mesenteric contusion 0 (0 %) 2 (4.4 %)
Mild intrauterine adhesion 5 (16.1 %) 2 (4.4 %)
Secondary dysmenorrhea 0 (0 %) 0 (0 %)
Adenomyosis 0 (0 %) 0 (0 %)
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the study, further studies with larger sample sizes and pro-
spective design are required to validate our findings.
During the hysteroscopic resection of the type II submu-
cous myomas, it can inevitably increase the injury to the
uterine endometrium in order to completely resect the my-
omas, which will sow the seeds of intrauterine adhesions.
Therefore, adequate size of type II submucous myomas is
important for carrying out the hysteroscopic myomectomy
[14]. In addition, attention should be paid to protect the
myoma pseudocapsule, especially the uterine endometrium
[28]. These can not only prevent the risk of the uterine
adhesion due to large surgical scope, but lay a basis for sub-
sequent pregnancy. Meanwhile, we also take care to protect
the myometrium surrounding the myoma during the hys-
teroscopic myomectomy, which can also reduce the risk of
intrauterine adhesions. Similarly, during the process of
laparoscopic removal of submucous myomas, care should
be also taken to preserve the intact of the endometrium
when the myomas were resected. Blunt stripping should be
conducted while enucleating the myoma adjacent to the
uterine mucous layer. During the process of blunt stripping,
application of energy equipment should be avoided. During
the process of dissecting the serosal layer using unipolar
electrode, a mode of electrocoagulation and electrosection
with an electrocoagulation power of 40 W was used in this
study. In case that the endometrium was damaged, the
wound of the uterus was sutured in layers to ensure the
accurate myometrial apposition and prevent the risk of
postoperative intrauterine adhesion. Since the submucous
myomectomy can inevitably cause a large resection cavity,
attention should be paid while handling the residual cavity
of the myometrium during the suture. In this study, inter-
rupted “8” figure suture was used for hemostasis and
running sutures was used for the residual cavity of the
myometrium, which helps to tighten the sutures and
hemostasis. We did not use electric coagulation hemostasis.
This can prevent local cavity infection and thus avoid the
risk of uterine rupture during pregnancy. In our series, we
observed 16.1 % (5/40) of uterine adhesions (synechiae) in
the hysteroscopic group and 4.4 % (2/45) of uterine adhe-
sions in the laparoscopic group. We speculate these may be
associated with the size of the myoma. During the hystero-
scopic removal of large myoma, cutting a relatively large
“window” on the uterine mucosa is needed which destroy
the relatively more endometrium and thus increases the
risk of the incidence of the uterine adhesions. Whereas the
laparoscopic removal of myomas was performed through
the uterine serosal surface which relatively preserve the
endometrium and reduce the risk of the incidence of the
uterine adhesions.
Conclusions
Both techniques are feasible for type II submucous myomas
of diameter between 3 and 5 cm. Laparoscopic operation
had higher advantages in type II submucous myomas of
greater than 4 cm in diameter whereas hysteroscopic
operation higher advantages in type II submucous myo-
mas of lower than 4 cm in diameter. Further studies
with a larger number of samples are still necessary for
confirming our findings.
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